Interview with Paul Flapper, General Manager, Shire International Licensing BV…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Address: Strawinskylaan six hundred fifty-nine
1 077 XX Amsterdam
,Netherlands
Tel: +31 (0) 20 364 00 74
Web: http://www.shirenederland.nl/
Shire is a global specialty biopharmaceutical company founded in 1986. Shire aims those with life-limiting illnesses helping a better life.
Shire seeks to achieve this through multiple therapeutic areas in medicine specialist to develop, produce and sell. Shire’s activities are housed in two divisions:
‘Human Genetic Therapies’ focused on genetic diseases such as Hunter syndrome, Fabry disease and hereditary angioedema.
Specialty Products’ represents the therapeutic areas of ADHD, Nephrology, Hematology and Gastroenterology.
Shire group is structured as two autonomous businesses supported by global corporate functions; business unit structure that enables small molecule entities to thrive under Shire Specialty Pharma and protein therapeutics to emerge from Shire Human Genetic Therapies
Shire Human Genetics Therapies delivers medicine in the therapeutic area lysosomal storage diseases, namely Fabry disease and Hunter syndrome.
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
See our Cookie Privacy Policy Here
